NCT04974333

Brief Summary

The SANENT trial is a primary care-based, prospective, two-arm, randomized controlled, open-label, blinded-endpoint study with the aim to compare a diabetes management strategy using an information board and a mobile application versus standard care in patients with uncontrolled type 2 diabetes. This trial aims to recruit 1440 type 2 diabetes patients during a period of six months until the requested number of participants have been achieved. The total length of the intervention will be one year. The SANENT trial protocol is presented according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) recommendations

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,512

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

July 23, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

October 4, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2024

Completed
Last Updated

March 31, 2022

Status Verified

March 1, 2022

Enrollment Period

1.9 years

First QC Date

June 30, 2021

Last Update Submit

March 17, 2022

Conditions

Keywords

diabetes type 2mobile health technologydiabetes controlinterventionlifestyle habits

Outcome Measures

Primary Outcomes (1)

  • HbA1C

    Change in HbA1C

    12 months

Secondary Outcomes (9)

  • Blood lipids changes

    12 months

  • Blood pressure changes

    12 months

  • Body mass index

    12 months

  • Treatment compliance change

    12 months

  • Mental health improvement

    12 months

  • +4 more secondary outcomes

Study Arms (2)

Mobile health application

EXPERIMENTAL

Participants assigned to the intervention group will use a mobile application on their smart phones that will assist the patients with their diabetes control, provide and update information on their clinical history, offer a monitoring their nutritional and physical activity habits as well as anthropometric measurements, provide recommendations how to improve on nutritional habits and physical activity behavior, assist in planning and reminding on clinical appointments. The duration of the intervention will be 12 months. Each patient will be invited to follow-up visits and measurements each three months (month 3, month 6, month 9 and month 12).

Device: Mobile health application on phone

Standard care

NO INTERVENTION

Participants assigned to the control arm will continue their regular standard diabetes care without mobile health technology assistance.

Interventions

Patients will use a mobile app on their smart phones

Mobile health application

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women treated for type 2 diabetes with an HbA1C\>8.5%;
  • ≥20 years-of-age;
  • Signed up for diabetes treatment and control in one of the participating primary healthcare practices.
  • Having access to a mobile phone (or having a family member who will help them in sending, understanding, and retrieving messages and information provided in Spanish language through the mobile application)

You may not qualify if:

  • Participants who are pregnant, within 3 months postpartum or planning pregnancy during the trial;
  • Breastfeeding;
  • Serious medical condition (i.e. dialysis treatment);
  • Having been admitted to hospital within the last 3 months for hyperglycemia or hypoglycemia;
  • Not permanent residents of the states where the study is conducted.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Coordinacion Clinica de Educacion e Investigacion en Salud Medicina Familiar

Mexico City, Mexico City, 010710, Mexico

RECRUITING

Unidad de Medicina Familiar 33

Chihuahua City, 31204, Mexico

RECRUITING

Establecimiento salud: Centro de Salud Urbano Zona Oriente "La Vurgencita"

Colima, 28047, Mexico

RECRUITING

Related Publications (1)

  • Barengo NC, Apolinar LM, Estrada Cruz NA, Fernandez Garate JE, Correa Gonzalez RA, Diaz Valencia PA, Gonzalez CAC, Rodriguez JAG, Gonzalez NC; SANENT Study Group. Development of an information system and mobile application for the care of type 2 diabetes patients at the primary care level for the health sector in Mexico: study protocol for a randomized controlled, open-label trial. Trials. 2022 Apr 4;23(1):253. doi: 10.1186/s13063-022-06177-0.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Nelly Cisneros Gonzalez, MD

    Consejo General de Salud

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Leticia Manuel Apolinar, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2021

First Posted

July 23, 2021

Study Start

October 4, 2021

Primary Completion

August 31, 2023

Study Completion

February 28, 2024

Last Updated

March 31, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations